Trial Profile
A Phase II Open-label Study With the Anti-PD-L1 Atezolizumab Monoclonal Antibody in Combination With Bevacizumab in Patients With Advanced Chemotherapy Resistant Colorectal Cancer and MSI-like Molecular Signature
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 04 Oct 2021 Status changed from recruiting to discontinued (The results of the interim analysis showed that the efficacy in the MSS subgroup (MSI like) isinferior to the expected, and this situation is very unlikely to be reversed if the trial isfully completed.)
- 05 Oct 2020 Planned End Date changed from 1 Mar 2020 to 1 Mar 2021.
- 05 Oct 2020 Planned primary completion date changed from 1 Mar 2020 to 1 Nov 2020.